December 7, 2017 - By Winifred Garcia

The stock of AXIM BIOTECHNOLOGIES INCORPORATED (OTCMKTS:AXIM) registered a decrease of 35% in short interest. AXIM’s total short interest was 35,100 shares in December as published by FINRA. Its down 35% from 54,000 shares, reported previously. With 30,700 shares average volume, it will take short sellers 1 days to cover their AXIM’s short positions.

The stock decreased 0.74% or $0.05 during the last trading session, reaching $6.75. About 14,903 shares traded. AXIM Biotechnologies, Inc. (OTCMKTS:AXIM) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

AXIM Biotechnologies, Inc., a biotechnology company, focuses on the treatment of pain, spasticity, anxiety, and other medical disorders with the application of cannabinoids based products. The company has market cap of $368.31 million. It also focuses on the research, development, and production of pharmaceutical, nutraceutical, oral health, and cosmetic products, as well as procurement of genetically and nano-controlled active ingredients. It currently has negative earnings. The firm was formerly known as Axim International Inc. and changed its name to AXIM Biotechnologies, Inc. in July 2014.

More notable recent AXIM Biotechnologies, Inc. (OTCMKTS:AXIM) news were published by: which released: “Axim Biotechnologies: A Great Stock To Sell Short” on May 02, 2017, also with their article: “Marijuana Stocks: Short AXIM Biotechnologies…If You Can Borrow And Finance …” published on November 23, 2016, published: “3 Things You Need to Know About Marijuana Stock Axim Biotechnologies” on July 18, 2017. More interesting news about AXIM Biotechnologies, Inc. (OTCMKTS:AXIM) were released by: and their article: “AXIM Biotechnologies’ Recent Patent Does Not Offer Value To Investors” published on October 16, 2017 as well as‘s news article titled: “AXIM Biotech Files Patent on Controlled Release Chewing Gum to Provide Opioid …” with publication date: June 23, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.